You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
晨光生物(300138.SZ)擬斥235萬元參設藥物研發公司 積極佈局中藥提取領域
格隆匯 10-31 20:03

格隆匯10月31日丨晨光生物(300138.SZ)公佈,公司第四屆董事會第十一次會議審議通過了《關於合作建立藥物研發公司的議案》,為積極佈局中藥提取領域,為第三步大健康產業做準備,公司擬與北京華醫神農醫藥科技有限公司(“華醫神農”)及李衞民、朱賀年合作建立藥物研發公司,在藥物研究與技術開發、新藥研發、健康產品研發、醫療器械研發、診斷試劑與技術研發等方面加強合作,對內、對外承接上述範圍的技術及產品開發業務。

2019年10月31日,公司與華醫神農及李衞民、朱賀年簽署了《合作協議》,各方共同以現金出資,合作建立藥物研發公司,新組建公司註冊資本為500萬元,公司出資235萬元,佔47%的股份;華醫神農出資215萬元,佔43%的股份;李衞民、朱賀年各出資25萬元,各佔5%的股份。

擬設立河北晨光神農醫藥科技有限公司(暫定名,以註冊後的名稱為準)經營範圍:藥品、保健食品、功能性食品、食品添加劑、醫療器械、診斷試劑的技術開發、技術轉讓、技術培訓、技術諮詢、技術服務。

為積極佈局中藥提取領域,為第三步大健康產業做準備,公司擬與華醫神農及李衞民先生、朱賀年先生合作建立藥物研發公司,在藥物研究與技術開發、新藥研發、健康產品研發、醫療器械研發、診斷試劑與技術研發等方面加強合作,對內、對外承接上述範圍的技術及產品開發業務。

此次投資有利於公司中藥提取物業務發展,符合公司的整體長期戰略規劃,不會對公司的財務及經營狀況產生不利影響,不存在損害公司及全體股東利益的情形。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account